Audited Results as at 31.03.2026. Earlier results were missed out in uploading and hence this revised file is attached herewith.
TRANSPEK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 11.0 pts less than Nifty Microcap 250 and 11.1 pts less than its Commodity Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Transpek Industry Limited reported audited standalone and consolidated results for FY2026 ended March 31, 2026. Revenue from operations declined to Rs 62,119.90 lakhs from Rs 64,985.31 lakhs in the previous year, representing approximately 4.4% revenue decline. Profit after tax stood at Rs 4,564.81 lakhs compared to Rs 4,874.07 lakhs in FY2025, showing a 6.3% decline in profitability. EBITDA margin showed compression as operating profit declined while depreciation remained substantial at Rs 4,864.05 lakhs. The Board has recommended a dividend of Rs 20 per equity share (200%) for the year. Auditors have provided an unmodified (clean) opinion on both standalone and consolidated financial statements. The company has a wholly-owned subsidiary, Transpek Creative Chemistry Private Limited.
The stock may face mild negative sentiment due to revenue and PAT decline. However, the clean audit opinion and 200% dividend payout signal financial stability and management confidence, which could support shareholder returns despite the underwhelming financial performance.